With over 20 years of experience in laboratory-based drug and formulation discovery research, I specialise in in vivo drug efficacy, pharmacokinetics, pharmacodynamics, biodistribution/bioavailability and toxicology. My focus includes optimising drug delivery for maximum efficacy in chronic pain, inflammatory, and neurological/psychiatric disease models. My work has investigated the therapeutic potential of well over 100 therapeutic small molecules, peptides, peptidomimetics, mRNA and different formulations thereof for in vivo efficacy, pharmacokinetics and toxicology. Most of this work was perfromed by myself, where the whole gamut of the PK research, from design, achieving AEC approval, performance of the preclinical in vivo work, LCMS/MS quantitation and data processing, was driven by me. My experience in in vivo pharmacokinetic and efficacy studies spans rats, mice, guinea pigs, rabbits, and sheep, encompassing full LCMS quantification in various tissue types (inc. brain, liver, kidney, adipose etc) and biological fluids (whole blood, plasma/serum, cerebrosinal fluid, urine). I have contributed to human clinical trials, using highly sentitive  LCMS methods for quantifying drug concentrations in human biological fluids. As a registrant of the Australasian College of Toxicology and Risk Assessment (RACTRA),and serving as an Associate Editor at Frontiers in Neurological Drugs and a Review Editor at Frontiers in Pharmacology and Frontiers in Drug Discovery, I am actively involved in advancing the scientific community.

 

My expertise at PharmEthos encompasses guiding our client for optimal design and execution of their preclinical in vivo efficacy and PK experiments, drug extraction and quantification via LCMS/MS. This includes assisting our clients to maximise the efficiency of approval of their ethics applications to animal ethics committees, meeting regulatory, welfare and international guideline standards.

​

For many years, my work has been supported by major pharmaceutical and biotech companies such as Pfizer, Glaxo, AstraZeneca, Atai, Aptar, and Preveceuticals. I excel in developing, optimising, and validating methods for drug testing, with extensive experience in GLP, NATA-accredited labs, GCP, and clinical trials.

​

I have acted as a Category B member (Scientific Advisor) and Co-Chaired for an Animal Ethic Committee at the University of Queensland where I gained significant understanding of where the biggest issues in researcher miscommunication to the AEC lie. I am dedicated to the 3Rs (Replacement, Reduction, Refinement) in preclinical research and strictly adhere to local and global ethics standards for animal use. The goal of PharmEthos is to apply our knowledge to your project to, simply, give you the best shot of success in your preclinical in vivo projects, from start to finish. 

​

Through PharmEthos, we provide expert guidance on optimising preclinical pharmacology, toxicology, and animal ethics solutions. Our services aim for rapid AEC approval and best possible scientific outcomes through proper exeprimental deisgn at conception, all within limits of the Australian Codes, the 3Rs and maintaining a high integrity of animal welfare. 

​

​